From genes to metabolomics in renal cell carcinoma translational research.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Urinary metabolites in association with kidney cancer risk.Carcinogenesis · 2025
   Article
2. Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma.World journal of surgical oncology · 2022
   Article
3. Machine learning distilled metabolite biomarkers for early stage renal injury.Metabolomics : Official journal of the Metabolomic Society · 2019
   Article
4. Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan.Nature communications · 2019 · on this map
   Article
5. An Integrated Lipidomics and Phenotype Study Reveals Protective Effect and Biochemical Mechanism of Traditionally UsedFrontiers in pharmacology · 2018
   Article

Corrections and comments

• Comment on
  Metabolism of kidney cancer: from the lab to clinical practice.2013

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as